Stay updated on IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial
Sign up to get notified when there's something new on the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page.

Latest updates to the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page
- Check4 days agoChange DetectedNew site revision v3.3.4 appears in the history, indicating a minor update; no study data or page content were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedAdded Outcome Measures (Results), References, and Study Status, and updated revision to v3.3.3; removed HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.2%

- Check40 days agoChange DetectedThe record history adds a 'Results Posted' entry and updates multiple results-related sections (Outcome Measures, Adverse Events, Baseline Characteristics, Participant Flow, IPD Sharing, Study Description/Design) with a new version dated 2025-11-14, replacing the previous 'Results Submitted' entry.SummaryDifference0.6%

- Check47 days agoChange DetectedThe page history shows a new revision v3.3.2 added and the previous revision v3.3.1 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check54 days agoChange DetectedThe latest version adds a 'Results Submitted' entry and removes 'No Results Posted' in the History. It is labeled Revision: v3.3.1.SummaryDifference0.1%

- Check62 days agoChange DetectedRemoved a site-wide operating-status notice about government funding and NIH/Clinical Center status (including links to cc.nih.gov and opm.gov). The notice previously appeared at the top of the page.SummaryDifference0.2%

Stay in the know with updates to IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page.